meta
|
evidence
COVID-19
Living systematic review and meta-analysis
***** adjuvant therapies
***** anti-inflammatoty and immuno-therapy
***** antiandrogenic
***** antiviral and associated therapy
***** control
***** Drugs for acid related disorders
***** miscellaneous
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
vaccines
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus)
Ad26.ZEBOV ()
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine)
CanSino (Convidecia)
Covishield (Oxford/AZ formulation)
Janssen AD26 vaccine (JNJ-78436735)
Sputnik V (Gam-COVID-Vac)
SPUTNIK-LIGHT
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
***** Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
adverse events
intracranial hemorrhage
ischemic stroke
Myocardial infarction
pulmonary embolism
serious adverse events (SAE), any
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance